Immunotherapy after surgery for liver cancer with microscopic vessel invasion
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving an immunotherapy drug (sintilimab) after surgery helps keep liver cancer with microscopic blood vessel invasion from coming back. It may improve chances of staying cancer-free after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had your liver cancer completely removed by surgery.
- Your pathology report shows cancer cells in small blood vessels around the tumor (called microvascular invasion).
- You are between 18 and 75 years old.
- You have not had any prior cancer treatment (like chemotherapy or radiation) for this liver cancer.
- Your cancer has not spread outside the liver or into major blood vessels.
- Your liver function is good enough (Child-Pugh A or mild B) and you can take care of yourself (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving two medicines (an immunotherapy and a targeted therapy) after surgery can help prevent liver cancer from coming back in people with a specific type of tumor clot in the liver's main vein. If you've had surgery to remove the cancer and meet the health criteria, this treatment may lower your risk of recurrence.
This trial tests a combination of immunotherapy (sintilimab), a targeted anti-angiogenic drug (bevacizumab biosimilar), and liver-directed therapies (TACE-HAIC) before and after surgery for hepatocellular carcinoma that has spread to the portal vein. The goal is to see if this approach improves outcomes for patients with advanced but resectable liver cancer.
This trial tests two drugs, sintilimab and bevacizumab, given before surgery to treat liver cancer that can be removed. It's for people with a certain stage of liver cancer who haven't had other treatments.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This study tests whether giving focused local treatment (like radiation or surgery) after a combination of two drugs, sintilimab and lenvatinib, can help control advanced liver cancer that has spread to a few other places. The goal is to see if this approach can shrink tumors and possibly extend life.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.